Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival
Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
The leading risk factor for corneal transplant rejection is abnormal blood vessel growth of
the host bed. Vascular endothelial growth factor (VEGF) is thought to be a mediator of this
corneal neovascularization (NV), therefore we would like to test the safety and efficacy of
local VEGF blockade in the promotion of graft survival in high risk corneal transplants.